Aims: Microglia and infiltrated macrophages play important roles in inflammatory processes after ischemic stroke. Modulating microglia/macrophage polarization from proinflammatory phenotype to anti-inflammatory state has been suggested as a potential therapeutic approach in the treatment of ischemic stroke. Melatonin has been shown to be neuroprotective in experimental stroke models. However, the effect of melatonin on microglia polarization after stroke and underlying mechanisms remain unknown.
| INTRODUC TI ON
Stroke is one of the primary causes of death and disability worldwide.
Ischemic stroke accounts for approximately 85% of total stroke. A large number of reports in the past few decades have shown that neuroprotective strategies target to only neurons fails to produce a better outcome after stroke. 1, 2 Accumulating research demonstrates that cytokine-dependent microenvironments play crucial roles in the progress of stroke. 3 New therapeutic strategies toward the regulations of microenvironment to promote functional outcomes and tissue repair after stoke have recently attracted tremendous attention.
Inflammatory responses are one of the main pathophysiological processes involved in secondary injury after stroke. 4 Microglia are resident immune cells in the central nervous system (CNS), contributing to the maintenance of CNS homeostasis in the normal condition. Microglia can drastically alter their phenotypes and functions (pro-inflammation, anti-inflammation and et al.) in response to microenvironmental changes. 5, 6 The pro-inflammatory phenotype expresses signature markers including CD86 and CD68 and tends to release destructive mediators such as tumor necrosis factor (TNFα), inducible nitric oxide synthase (iNOS), interleukin-1β (IL-1β), and nitric oxide (NO). 7 In contrast, the anti-inflammatory phenotype characterized by expression of molecules such as arignase1, Ym1/2, CD206, and produces beneficial mediators, including interleukin-4 (IL-4), interleukin-10 (IL-10), and transforming growth factor-β (TGFβ). Dual roles of microglia are observed at different stages after stroke. [7] [8] [9] Microglia and infiltrated macrophage initially polarize toward a neuroprotective anti-inflammatory phenotype after stroke, but gradually transform into a detrimental pro-inflammatory phenotype. In vivo and vitro studies revealed that inhibiting pro-inflammatory microglia phenotype and/or stimulating anti-inflammatory microglia state were neuroprotective. 7, 10, 11 For example, some drugs, including ginkgolide B, 10 malibatol A, 11 thiamet G, 12 baicalein, 13 isosteviol sodium, 14 curcumin, 15 oxytocin, 16 and dimethyl fumarate 17 have been reported to protect against brain injury through regulating microglia/macrophage polarization and inflammatory responses in experimental models of brain ischemia or hypoperfusion.
Some physiological factors, such as hypothermia, [18] [19] [20] also altered microglia/macrophage phenotype. Exploring novel approaches that shift microglia/macrophage phenotype might provide more therapeutic strategy for ischemic stroke.
Melatonin (N-acetyl-5-methoxy-tryptamine) is a hormone secreted by the pineal gland, and its principal function is to regulate the circadian rhythm in mammals. Melatonin has been implicated in diverse physiological processes including mood behavior, blood pressure regulation, ovarian physiology, and osteoblast differentiation. 21 Its ability to readily cross the blood-brain barrier (BBB) makes melatonin an ideal neuroprotective agent. A large number of studies have demonstrated the involvement of melatonin in a variety of disease models, including stroke, traumatic brain injury, Alzheimer's disease, and Parkinson's disease. [22] [23] [24] [25] Administration of melatonin before or after cerebral ischemia has been shown to reduce infarct volume, enhance BBB integrity, and improve behavioral outcomes in animal models of stroke. 26, 27 Over the past decades, melatonin has emerged as a very potent free radical scavenger and antioxidant. It was able to directly protect against stroke-induced neuron cells death and ameliorate behavioral deficits by inhibition of oxyradicals and peroxynitrite production. Recently, an increasing number of studies have successively demonstrated that melatonin's neuroprotection against ischemic stroke derived from the inhibition of mitochondrial cytochrome C release [20] and the decrease of inflammatory responses. 28 However, the effect of melatonin on microglia/macrophage responses after stroke remains to be elucidated.
In the present study, we used a mouse model of dMCAO to analyze the effect of melatonin on microglia/macrophage polarization and inflammatory response after stroke. In vitro studies revealed the cellular mechanism of melatonin in regulating microglia/macrophage polarization. A microglia-neuron co-culture system was utilized to disclose whether melatonin may protect against ischemic neuronal death through microglia regulation. We found that melatonin promoted microglia/macrophage polarization toward anti-inflammatory phenotype through the activation of STAT3 pathway and thereby inhibited the neurotoxic effect of pro-inflammatory microglia to post-OGD neurons.
| MATERIAL S AND ME THODS

| Animals
For the study, 8-10 weeks-old male C57BL/6J mice weighing 23-25 g were purchased from the Vital River Laboratory Animal Technology Co., Ltd. All the animal experiments in this study were approved by the Institutional Animal Care and Use Committee of Capital Medical University and were performed in accordance with the National Institutes of Health Guidelines on the Care and Use of Laboratory Animals. A total of 36 mice were randomly assigned to three groups:
(i) sham (6 mice); (ii) stroke with vehicle treatment (15 mice); and (iii) stroke with melatonin treatment groups (15 mice). All behavioral least partially through shifting microglia phenotype from pro-inflammatory to antiinflammatory polarity in a STAT3-dependent manner.
K E Y W O R D S
inflammation, ischemic stroke, melatonin, microglia/macrophage polarization analysis was performed by independent investigators blinded to the treatment condition.
| Distal middle cerebral artery occlusion model and melatonin treatment
Distal middle cerebral artery occlusion (dMCAO) model was induced according to our previous report. 15 Briefly, anesthesia was induced with 2% isoflurane in N 2 /O 2 (70%:30%) mixture. A ~ 2 cm skin incision was created between the right margin of the orbit and the tragus, and the temporalis muscle was dissected to expose right zygomatic arches and squamosal bone. A craniotomy was made, and the right middle cerebral artery (MCA) was exposed after 
| Quantification of infarct volume
Infarct volume was measured at 3 days after ischemia on TTCstained sections. The mice were deeply anesthetized with chloral hydrate and decapitated. The brains were removed and coronally sliced to 1 mm sections in a brain mold. Then, the brain slices were incubated in 2% 2, 3, 5-triphenyltetrazolium chloride (TTC; Sigma-Aldrich) solutions at 37°C for 30 min. The infarct area was calculated as the area of the contralateral hemisphere minus the noninfarct area of the ipsilateral hemisphere using National institutes of Health ImageJ software. The infarct volume was obtained by the sum of the infarct areas in all sections multiplying by the slice thickness.
| Adhesive removal test
An adhesive removal test was used to determine the sensorimotor deficits at 1 and 3 days after cerebral ischemia, as previously described. 15 In brief, an adhesive tape (~ 50 mm 2 ) was applied to the distal radial region of the right forelimb. The mice removed the tape using their left forelimbs in response to the tactile stimulations. The times to contact and to remove the tape were recorded. Each mouse was tested three times with a cutoff time of 120 seconds per trial.
The data are presented as the mean times to contact or the mean times to remove the tape from three trials.
| Modified garcia score test
The modified Garcia Score test was used to assess the behavioral function at 1 and 3 days after dMCAO. The modified Garcia Score system is composed of 5 tests: 15 body proprioception, vibrissae touch, limb symmetry, lateral turning, and forelimb walking. The total score for the modified Garcia Score ranges from 0 (maximum deficits) to 15 (no deficits). vine serum (Gibco) and 1% penicillin-streptomycin (Gibco) at 37°C in CO 2 /air (5% /95%) mixture. 29 We used OGD neuron-conditioned medium (CM) to stimulate resting microglia. To induce ischemic injury, N2a cells were subjected to OGD for 3 hours and then returned to 95% air, 5% CO 2 , and normal glucose medium for 12 hours. To obtain pro-inflammatory microglia, the OGD neuron CM (1:1 ratio to microglia media) was added to microglia cultures for 6, 12, or 24 hours.
| Pro-inflammatory microglia cell model and melatonin treatment
Control microglia were treated with medium collected from normal neuron without OGD. For dose-response studies, IL-1β mRNA level was measured using real-time PCR after BV2 was stimulated by CM or CM plus melatonin (100, 200, or 400 mM) for 12 hours.
| Neuron-microglia co-culture
BV2 microglia and N2a cells were cocultured using transwell cell culture inserts (Dow Corning, Corning). The cell density ratio of microglia to neurons is 1:10. Briefly, microglia growing on culture inserts were treated with CM followed by melatonin or vehicle for 12 hours.
Medium was removed, and microglia washed with fresh medium 3 times. For N2a culture, neuronal cultures growing in 24-well plate were subjected to OGD for 3 hours. Medium was removed, and neuron-microglia co-cultures were generated by adding the microglia inserts on top of post-OGD neuronal cultures. The co-culture was maintained for 12 hours before the microglia inserts were removed. 
| Real-time PCR
Real-time PCR was performed as described in our previous report. 15 The total RNA from the ischemic brain or from the BV2 cells was isolated using TRIzol Reagent (Invitrogen) and was reverse-transcribed into cDNA using by SuperScript II Reverse Transcriptase (Invitrogen) to detect gene expression according to manufacturer's instructions.
Real-time PCR was performed using quantitative PCR (ABI 7500, Thermo Fisher Scientific) with corresponding primers ( Table 1, Invitrogen) in the presence of a fluorescent dye (RT2 SYBR® Green FAST Mastermixes, QIAGEN). Each experimental group was performed in triplicate to obtain the cycle time (CT) mean. GAPDH was used as a reference gene for quantification. The expression of mRNAs was presented as fold changes vs. sham control. 
| Western Blot
| Statistical analysis
The number of mice in each group was determined using power analyses, according to our past experience with similar measurements (α = 0.05 and β = 0.20). All data were reported as mean ± SEM.
Comparison of means between two experimental groups was evaluated by the Student's two-tailed t-test. Differences in means among multiple groups were analyzed using one-or two-way analysis of variance followed by the Bonferroni test. Statistical significance was set at P < .05.
| RE SULTS
| Poststroke administration of melatonin reduces infarct volume and improves sensorimotor functions after dMCAO
Mice were subjected to dMCAO and then to receive injections of either melatonin (i.p., 20 mg/kg) or vehicle at the onset of cerebral ischemia and 24 hours after dMCAO. As shown ( Figure 1A) , melatonin significantly reduced infarct volume 3 days after dMCAO. To determine the effect of melatonin treatment on functional outcomes after dMCAO, sensorimotor deficits were evaluated by the adhesive removal and modified Garcia score system 1 and 3 days after ischemia.
Melatonin treatment markedly reduced the time to touch the tape ( Figure 1B ) and the time to remove the tape ( Figure 1C ) 3 days after stroke as compared to vehicle-treated mice. Moreover, administration of melatonin reversed the stroke-induced sensorimotor deficits in body proprioception ( Figure 1D ), limb symmetry ( Figure 1F ), lateral turning ( Figure 1G ), and forelimb walking ( Figure 1H ), resulting in improved total neurological scores on days 1 and/or 3 after stroke ( Figure 1I ). There was no significant difference in vibrissae touch ( Figure 1E ) between vehicle and melatonin-treated groups. These results indicate that melatonin treatment improved the short-term behavioral functions after dMCAO.
| Melatonin shifts microglia/macrophage polarization toward anti-inflammatory phenotype 3 days after dMCAO
The polarized microglia/macrophages are commonly distinguished by their expression of feature genes. We measured the mRNA expression of microglia/macrophage phenotype markers in the ischemic brain using real-time PCR at 3 days after dMCAO (Figure 2 ). Our data show that the expression of pro-inflammatory phenotype markers (CD11b, CD86, iNOS, IL-6, and TNF-α) and anti-inflammatory phenotype markers (CD206, Arg-1, YM1/2, TGF-β, and IL-10) was all increased greatly after dMCAO. However, the pro-inflammatory markers increased much more than anti-inflammatory markers.
TA B L E 1 Primers for real-time PCR
Melatonin treatment enhanced the expression of above-mentioned anti-inflammatory markers while inhibited the expression of proinflammatory markers in the ischemic brain at 3 days after dMCAO. We observed that the mRNA expression of IL-1β in BV2 cells was also significantly increased 12 hours after OGD neuron CM treatment ( Figure 3C ). Melatonin at 200 or 400 nM inhibited CM-induced IL-1β production in BV2 cells. There was no significant difference in IL-1β level between 200 and 400 nM treated groups. Therefore, 200 nM was used as the optimal dose for later experiments.
| Melatonin promotes microglia polarization toward anti-inflammatory state and alleviates the proinflammatory responses in vitro
We further found that the mRNA expression of pro-inflamma- 
| Melatonin regulates microglia polarization toward pro-inflammatory phenotype through STAT3 pathway
STAT3 plays a critical role in macrophage polarization. 30, 31 In order to elucidate the mechanism underlying melatonin's regulation on microglia polarization, we examined the protein levels of STAT3 and p-STAT3 in BV2 cells. The ratio of p-STAT3/STAT3 expression was decreased in pro-inflammatory microglia stimulated by CM compared with resting microglia, whereas melatonin treatment reversed this alteration. Administration of melatonin dramatically upregulated the relative expression of p-STAT3/STAT3 ( Figure 4A ). To further clarify the underlying role of STAT3 pathway, stattic was used to inhibit activation of STAT3. We found that the mRNA expressions of pro-inflammatory phenotype markers were increased, whereas the mRNA expressions of anti-inflammatory phenotype markers were decreased when stattic was added to CM-stimulated BV2 cells in the presence of melatonin ( Figure 4B,C) . These results indicate that melatonin shifts microglia from pro-inflammatory phenotype to antiinflammatory phenotype polarization state, at least in part, through STAT3 activation.
| Melatonin reduces the neurotoxic effect of pro-inflammatory microglia on post-OGD neurons
We demonstrate that poststroke treatment of melatonin increased the expression of anti-inflammatory phenotype markers and reduced the expression of pro-inflammatory phenotype markers in the brain at 3 days after dMCAO, which is accompanied by reduced cerebral inflammation and infarct volume (Figure 1 and Figure 2 ). To further confirm that melatonin could indirectly protect against ischemic neuronal death through microglia regulation, a microglia-neuron coculture system was used ( Figure 5A ). Pro-inflammatory phenotype microglia enhanced post-OGD neuronal death, as indicated by increased LDH release and decreased cell viability results, which was significantly reversed in melatonin-treated CM (Figure 5B,C) . These findings suggest that melatonin converted microglia polarization toward anti-inflammatory phenotype and attenuated pro-inflammatory phenotype-potentiated neurotoxic effect on ischemic neuronal death.
| D ISCUSS I ON
Melatonin is a natural neurohormone produced mainly in pineal gland and is a powerful antioxidant, free radical scavenger, and a regulator of circadian rhythm. 32 The decreased melatonin levels were observed in acute ischemic stroke patients or in the experimental F I G U R E 2 Melatonin shifts microglia/macrophage polarization toward anti-inflammatory phenotype 3 days after dMCAO. Mice were subject to dMCAO and received melatonin (20 mg/kg) injections at 0 and 24 hours after dMCAO. Peri-infarct areas of brains were collected at 3 days after dMCAO for RNA preparation. A, mRNA expression of pro-inflammatory genes (CD11b, CD86, iNOS, TNF-α, IL-6, and IL-1β) was measured by real-time PCR. B, mRNA expression of anti-inflammatory genes (CD206, Arg-1, YM1/2, TGF-β, and IL-10) was measured by real-time PCR. Data are mean± SEM. n = 6/group, **P < .01, ***P < .001 vs sham; ###P < .001 vs vehicle group, one-way ANOVA followed by Bonferroni post hoc test stroke models. 33 Accumulating evidence has endorsed that exogenous melatonin treatment plays a neuroprotective role in several CNS disorders, including ischemic stroke, through the mechanism of elimination free radical, regulation of circadian rhythm, inhibition of inflammatory responses. 24 In this study, a mouse distal middle cerebral artery occlusion model is used to demonstrate the protective effect of melatonin. We found that melatonin significantly reduced infarct volume and remarkably improved several aspects of sensorimotor function during the acute phase (3 days) of ischemic stroke.
Melatonin treatment was reported to improve long-term functional outcome after transient focal cerebral ischemia. 34 The cellular mechanism of melatonin-afforded protection can be multifaceted, including maintaining Ca 2+ homeostasis, 21 suppressing inflammatory response, 28 decreasing oxidative stress, 35 modulating stem cell survival, 35, 36 and attenuating endoplasmic reticulum stress. 37 In the present study, we specifically evaluated the effect of melatonin in the modulation of microglia phenotypic responses. These results can be replicated in OGD neuron CM-treated microglia, suggesting that melatonin treatment can help to reduce the pro-inflammatory response and increase anti-inflammatory response in microglia upon ischemic neuronal injury. Furthermore, our in vitro studies confirmed that melatonin reduced the neurotoxic effect of pro-inflammation microglia on post-OGD neurons. It is known that microglia/macrophage polarization could be regulated by cytokine-dependent microenvironments. For instance, interferon γ (IFN-γ) and TNF-α can induce and maintain pro-inflammation microglia polarization, whereas IL-4 or IL-10 can initiate anti-inflammatory polarization. [39] [40] [41] Therefore, the reduced inflammatory mediator release after melatonin treatment could improve microenvironment and further ameliorate inflammation and/or promote brain recovery.
Microglia/macrophage polarization is modulated by many transcription factors, such as STATs and PPAR-γ 6, 42, 43 STAT3 was demonstrated to play a dominant role in IL-10-mediated anti-inflammatory effects in human macrophages. 8 In addition, STAT3 appeared to be critical in regulating macrophage/microglia polarization to anti-inflammatory phenotype in the TBI brain. 30 Besides, resveratrol was reported to suppress the LPS-induced pro-inflammatory response in microglia cells through the activation of STAT3 pathway. 31 In this study, melatonin significantly increased the expression of phosphorylated STAT3 in microglia. Melatonin-induced anti-inflammatory polarization was abolished by the STAT3 inhibitor, stattic.
These results further illustrated that melatonin regulates microglia polarization, at least in part, through STAT3 pathways. Here, we reveal the role of STAT3 in melatonin-induced anti-inflammatory polarization in cultured microglia. Nevertheless, in vivo study is still required to perform to confirm the underlying mechanism.
| CON CLUS ION
We demonstrate that melatonin has a profound regulatory effect on microglia/macrophage polarization toward anti-inflammatory phenotype through STAT3 pathway. Our findings suggest that melatonin post-treatment reduces ischemic stroke-induced brain damage and F I G U R E 4 Melatonin shifts microglia polarization via the activation of STAT3 signaling pathway. A, Representative Western blots and quantification of p-STAT3 and STAT3 in the BV2 microglia treated OGD neuron CM with/without 200 nM melatonin. STAT3 inhibitor stattic was used as a negative control. B,C, The importance of STAT3 in the effect of melatonin on microglia polarization. Stattic (5 μM) was added to OGD-treated microglia for 12 hours. B, mRNA expression of anti-inflammatory microglia/macrophage signature genes (CD11b, CD86, and iNOS) was measured by real-time PCR. C, mRNA expression of pro-inflammatory microglia/macrophage signature genes (CD206, Arg-1, YM1/2) was measured by real-time PCR. Data are mean ± SEM. n = 3/group, ***P < .001 vs vehicle group; ###P < .001 vs CM + vehicle; +P < .05, +++P < .001 vs CM + melatonin group, one-way ANOVA followed by Bonferroni post hoc test improves functional outcomes, providing new evidence that melatonin might be a promising therapeutic strategy for stroke.
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